213 related articles for article (PubMed ID: 11032029)
1. Additive effect between NF-kappaB subunits and p53 protein for transcriptional activation of human p53 promoter.
Benoit V; Hellin AC; Huygen S; Gielen J; Bours V; Merville MP
Oncogene; 2000 Sep; 19(41):4787-94. PubMed ID: 11032029
[TBL] [Abstract][Full Text] [Related]
2. Roles of nuclear factor-kappaB, p53, and p21/WAF1 in daunomycin-induced cell cycle arrest and apoptosis.
Hellin AC; Bentires-Alj M; Verlaet M; Benoit V; Gielen J; Bours V; Merville MP
J Pharmacol Exp Ther; 2000 Dec; 295(3):870-8. PubMed ID: 11082419
[TBL] [Abstract][Full Text] [Related]
3. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
4. Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis.
Liu J; Zhan M; Hannay JA; Das P; Bolshakov SV; Kotilingam D; Yu D; Lazar AF; Pollock RE; Lev D
Mol Cancer Res; 2006 Nov; 4(11):803-10. PubMed ID: 17077165
[TBL] [Abstract][Full Text] [Related]
5. Synergistic and opposing regulation of the stress-responsive gene IEX-1 by p53, c-Myc, and multiple NF-kappaB/rel complexes.
Huang YH; Wu JY; Zhang Y; Wu MX
Oncogene; 2002 Oct; 21(44):6819-28. PubMed ID: 12360408
[TBL] [Abstract][Full Text] [Related]
6. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.
Takimoto R; El-Deiry WS
Oncogene; 2000 Mar; 19(14):1735-43. PubMed ID: 10777207
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the NF-kappa B transcription factor increases Bax expression in cancer cell lines.
Bentires-Alj M; Dejardin E; Viatour P; Van Lint C; Froesch B; Reed JC; Merville MP; Bours V
Oncogene; 2001 May; 20(22):2805-13. PubMed ID: 11420692
[TBL] [Abstract][Full Text] [Related]
8. Nuclear factor - kappaB-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug.
Hellin AC; Calmant P; Gielen J; Bours V; Merville MP
Oncogene; 1998 Mar; 16(9):1187-95. PubMed ID: 9528861
[TBL] [Abstract][Full Text] [Related]
9. p53 upregulates death receptor 4 expression through an intronic p53 binding site.
Liu X; Yue P; Khuri FR; Sun SY
Cancer Res; 2004 Aug; 64(15):5078-83. PubMed ID: 15289308
[TBL] [Abstract][Full Text] [Related]
10. Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappaB and Myc/Max.
Kirch HC; Flaswinkel S; Rumpf H; Brockmann D; Esche H
Oncogene; 1999 Apr; 18(17):2728-38. PubMed ID: 10348347
[TBL] [Abstract][Full Text] [Related]
11. Transcription factors Oct-1 and NF-YA regulate the p53-independent induction of the GADD45 following DNA damage.
Jin S; Fan F; Fan W; Zhao H; Tong T; Blanck P; Alomo I; Rajasekaran B; Zhan Q
Oncogene; 2001 May; 20(21):2683-90. PubMed ID: 11420680
[TBL] [Abstract][Full Text] [Related]
12. p53 involvement in activation of the cytokeratin 8 gene in tumor cell lines.
Mukhopadhyay T; Roth JA
Anticancer Res; 1996; 16(1):105-12. PubMed ID: 8615594
[TBL] [Abstract][Full Text] [Related]
13. ING1 represses transcription by direct DNA binding and through effects on p53.
Kataoka H; Bonnefin P; Vieyra D; Feng X; Hara Y; Miura Y; Joh T; Nakabayashi H; Vaziri H; Harris CC; Riabowol K
Cancer Res; 2003 Sep; 63(18):5785-92. PubMed ID: 14522900
[TBL] [Abstract][Full Text] [Related]
14. Expression of prostate specific antigen (PSA) is negatively regulated by p53.
Gurova KV; Roklin OW; Krivokrysenko VI; Chumakov PM; Cohen MB; Feinstein E; Gudkov AV
Oncogene; 2002 Jan; 21(1):153-7. PubMed ID: 11791186
[TBL] [Abstract][Full Text] [Related]
15. Analysis of p53 transactivation through high-affinity binding sites.
Chumakov AM; Miller CW; Chen DL; Koeffler HP
Oncogene; 1993 Nov; 8(11):3005-11. PubMed ID: 8414502
[TBL] [Abstract][Full Text] [Related]
16. p53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells.
Bartke T; Siegmund D; Peters N; Reichwein M; Henkler F; Scheurich P; Wajant H
Oncogene; 2001 Feb; 20(5):571-80. PubMed ID: 11313989
[TBL] [Abstract][Full Text] [Related]
17. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells.
Baptiste N; Friedlander P; Chen X; Prives C
Oncogene; 2002 Jan; 21(1):9-21. PubMed ID: 11791172
[TBL] [Abstract][Full Text] [Related]
18. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
19. Distinct effects of annexin A7 and p53 on arachidonate lipoxygenation in prostate cancer cells involve 5-lipoxygenase transcription.
Torosyan Y; Dobi A; Naga S; Mezhevaya K; Glasman M; Norris C; Jiang G; Mueller G; Pollard H; Srivastava M
Cancer Res; 2006 Oct; 66(19):9609-16. PubMed ID: 17018618
[TBL] [Abstract][Full Text] [Related]
20. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells.
Jiang XH; Wong BC; Lin MC; Zhu GH; Kung HF; Jiang SH; Yang D; Lam SK
Oncogene; 2001 Nov; 20(55):8009-18. PubMed ID: 11753684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
